In re Nutramax Cosamin Marketing & Sales Practices Litigation
Opinion of the Court
TRANSFER ORDER
Before the Panel:
In opposing centralization, plaintiffs argue, inter alia, that there are only a few involved actions; the common factual issues are not especially complex; and plaintiffs’ counsel have agreed to cooperate in avoiding duplicative pretrial activity. After careful consideration of the record, however, we are not persuaded by these arguments. Indeed, the record demonstrates that complex scientific issues concerning the effectiveness of the involved Nutramax joint health products (Cosamin DS and/or Cosamin ASU) lie at the heart of this litigation. Plaintiffs allege that the scientific evidence, including various clinical studies, demonstrates that glucosamine hydrochloride and chondroitin sulfate— key ingredients in both Cosamin products — do not provide the joint health benefits advertised by Nutramax. In our view, extensive expert discovery likely will be required, as will one or more Daubert hearings. In addition, the proposed multistate class in the Northern District of Illinois action overlaps with the proposed state classes in the Southern District of Florida and Southern District of New York actions.
On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization under Section 1407 in the District of Maryland will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All actions share factual issues arising from allegations that Nutramax has made false and misleading advertising claims regarding the two Cosamin products. Centralization will eliminate duplicative discovery, prevent inconsistent pretrial rulings (in particular with respect to class certification and discovery issues), and conserve the resources of the parties, their counsel and the judiciary.
After weighing all factors, we have selected the District of Maryland as trans
IT IS THEREFORE ORDERED that pursuant to 28 U.S.C. § 1407, the actions listed on Schedule A and pending outside the District of Maryland are transferred to the District of Maryland and, with the consent of that court, assigned to the Honorable J. Frederick Motz for coordinated or consolidated pretrial proceedings.
SCHEDULE A
MDL No. 2498 — IN RE: NUTRAMAX COSAMIN MARKETING AND SALES PRACTICES LITIGATION
Southern District of California
Robert Dorfman v. Nutramax Laboratories, Inc., et al., C.A. No. 3:13-00873
Southern District of Florida
Demetri Spencer, et al. v. Nutramax Laboratories, Inc., et al., C.A. No. 1:13-21289
Northern District of Illinois
Chad Conrad v. Nutramax Laboratories, Inc., C.A. No. 1: 13-03780
Judge Marjorie O. Rendell took no part in the decision of this matter.
. That action and any other related federal actions are potential tag-along actions. See Panel Rules 1.1(h), 7.1 and 7.2.
. Although no constituent action is currently pending in the District of Maryland, that is not an impediment to its selection as the transferee district. See In re: BP p.l.c. Sec. Litig., 734 F.Supp.2d 1376, 1379 (J.P.M.L. 2010)
. We express no view on the degree; if any, to which pretrial proceedings in this docket should be coordinated with those in MDL No. 2491. That is a matter for the transferee judge to determine. See In re: Gerova Fin. Group, Ltd.., Sec. Litig., 816 F.Supp.2d 1381, 1382 (J.P.M.L. 2011).
Case-law data current through December 31, 2025. Source: CourtListener bulk data.